Abstract
Androgen-independent (AI) progression remains the main obstacle to improving the survival of patients with prostate cancer. Recently, we characterized changes in gene expression profile during AI progression in the prostate cancer model systems as well as the clinical specimens, and identified several genes, including bcl-2, bcl-xL, clusterin, insulin-like growth factor binding protein (IGFBP)-2, IGFBP-5 and heat shock protein 27, that are involved in the signal transduction pathways mediating resistance to various kinds of apoptotic stimuli. We then showed the efficacy of inactivating such antiapoptotic genes using antisense (AS) oligodeoxynucleotides (ODNs) to delay AI progression after androgen withdrawal. We further demonstrated the synergistic effects of AS ODN therapy combined with several treatments, such as cytotoxic chemotherapy, radiation and other molecular targeting therapies. In this review, we attempted to summarize the progress we have made in the field of AS ODN strategy against prostate cancer, and to discuss the preliminary data of the recently completed phase I clinical trials using AS ODNs as well as the future prospects of this therapy. The findings presented in this review may help clarify the significance of AS ODN therapy targeting relevant genes as an attractive alternative to conventional strategies for prostate cancer.
Keywords: Prostate cancer, androgen-independent progression, apoptosis, antisense oligodeoxynucleotide, clinical trial
Current Signal Transduction Therapy
Title: Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence
Volume: 1 Issue: 2
Author(s): Hideaki Miyake, Isao Hara, Masato Fujisawa and Martin E. Gleave
Affiliation:
Keywords: Prostate cancer, androgen-independent progression, apoptosis, antisense oligodeoxynucleotide, clinical trial
Abstract: Androgen-independent (AI) progression remains the main obstacle to improving the survival of patients with prostate cancer. Recently, we characterized changes in gene expression profile during AI progression in the prostate cancer model systems as well as the clinical specimens, and identified several genes, including bcl-2, bcl-xL, clusterin, insulin-like growth factor binding protein (IGFBP)-2, IGFBP-5 and heat shock protein 27, that are involved in the signal transduction pathways mediating resistance to various kinds of apoptotic stimuli. We then showed the efficacy of inactivating such antiapoptotic genes using antisense (AS) oligodeoxynucleotides (ODNs) to delay AI progression after androgen withdrawal. We further demonstrated the synergistic effects of AS ODN therapy combined with several treatments, such as cytotoxic chemotherapy, radiation and other molecular targeting therapies. In this review, we attempted to summarize the progress we have made in the field of AS ODN strategy against prostate cancer, and to discuss the preliminary data of the recently completed phase I clinical trials using AS ODNs as well as the future prospects of this therapy. The findings presented in this review may help clarify the significance of AS ODN therapy targeting relevant genes as an attractive alternative to conventional strategies for prostate cancer.
Export Options
About this article
Cite this article as:
Miyake Hideaki, Hara Isao, Fujisawa Masato and Gleave E. Martin, Antisense Oligodeoxynucleotide Therapy for Prostate Cancer Targeting Antiapoptotic Genes Involved in the Mechanism Mediating Progression to Androgen Independence, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012020
DOI https://dx.doi.org/10.2174/157436206777012020 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Mast Cell Pathway to Inflammation and Homeostasis: Pharmacolo- gical Insights
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Metabolomic Heterogeneity of Urogenital Tract Cancers Analyzed by Complementary Chromatographic Techniques Coupled with Mass Spectrometry
Current Medicinal Chemistry Non-coding RNAs in Exosomes: New Players in Cancer Biology
Current Genomics Long Term Prognosis in IgG4-Related Systemic Disease (ISD)
Current Immunology Reviews (Discontinued) Familial Colorectal Cancer Type X
Current Genomics Anti-Cancer Therapeutic Approaches Based on Intracellular and Extracellular Heat Shock Proteins
Current Medicinal Chemistry Immunological Aspects of Metritis in Dairy Cows: A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Design, Synthesis and Biological Evaluation of Novel 4-phenoxypyridine Derivatives Containing Semicarbazones Moiety as Potential c-Met Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Using Natural Product Inhibitors to Validate Hsp90 as a Molecular Target in Cancer
Current Topics in Medicinal Chemistry Sleep and the Immune System
Current Immunology Reviews (Discontinued) Synthetic Hammerhead Ribozymes as Therapeutic Tools to Control Disease Genes
Current Gene Therapy In-Vivo Gene Delivery by Sonoporation: Recent Progress and Prospects
Current Gene Therapy Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets The Role of the PERK/eIF2α/ATF4/CHOP Signaling Pathway in Tumor Progression During Endoplasmic Reticulum Stress
Current Molecular Medicine The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Noxa: Role in Cancer Pathogenesis and Treatment
Current Cancer Drug Targets Application of Molecular Imaging Technologies in Antitumor Drug Development and Therapy
Current Pharmaceutical Design Evolving Novel Chemical Entities for Management of Benign Prostatic Hyperplasia#
Mini-Reviews in Medicinal Chemistry